Sponsors of Part D legislation believe private Medicare Part D plans have been less effective than the government could be in negotiating price concessions.
That program, touted as a "down payment" on President Obama's pledge to provide health insurance coverage to all Americans, expands health coverage to families with incomes up to 300% of the federal poverty level. Other discussion has focused on the multi-billion dollar health IT package and the funding for comparative effectiveness research.
PART D PLAN EFFECTIVENESS
The legislation's sponsors believe that the private Medicare Part D plans have been less effective than the government could be in negotiating price concessions.
Backers of this legislation have highlighted the HHS Office of Inspector General (OIG) findings that plans under the Medicare prescription drug benefit have overcharged beneficiaries and the program since it began in 2006. The October 2007 report entitled "Medicare Part D Sponsors: Estimated Reconciliation Amounts for 2006" stated that an OIG review of a partially completed CMS audit of plans in 2006 resulted in $4.4 billion in overpayments.
More recently in a November 2008 report, OIG recommended that CMS should conduct the statutorily required bid audits in a timely manner as well as that "CMS could modify the entire bid audit process to: (1) identify instances in which errors are misrepresentations and (2) quantify errors that affect payments to plan sponsors. Modifying the bid audit process would enable CMS to pursue stronger enforcement and corrective actions."
Implementation of the latter would mark an important first step in shifting CMS' current rationale for bid audits, which is to improve future bid submissions, from a bid integrity/quality assurance perspective to an enforcement perspective. Even so, absent of fraud, CMS is still limited in its mid-plan-year enforcement capacities as it currently has no legal authority to revise the accepted bid amount or revise plan payments nor does it appear to have a mechanism to recoup erroneous payments after the reconciliation period is concluded.
Whether Congress will succeed in passing authorizing legislation or the federal government can implement an alternative government Part D option that can effectively compete with private plans is not yet clear. Equally unclear is if CMS will be given the legal authority or, in the current economic climate, provided the funding to pursue more vigorous enforcement of Part D. One thing that does appear clear is that Congressional democrats especially have expressed significant frustration to the frequency and efficacy of CMS oversight of Part D plans.
This column is written for informational purposes only and should not be construed as legal advice.
John Eriksen is a senior associate at Epstein, Becker and Green, P.C. in its Health Care and Life Sciences practice group and focuses primarily on health regulatory, compliance, managed care and transactional matters.
Upended: Can PBM Transparency Succeed?
March 6th 2024Simmering tensions in the pharmacy benefit management (PBM) industry have turned into fault lines. The PBMs challenging the "big three" have formed a trade association. Purchaser coalitions want change. The head of the industry's trade group says inherent marketplace friction has spilled over into political friction.
Read More
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
Inflation Reduction Act: Reforms to Patient Cost-Sharing
September 18th 2023Lower out-of-pocket costs for patients might put upward pressure on drug prices, as manufacturers face less price sensitivity, note Matthew Majewski and Rhett Johnson of Charles River Associates. But they also note that upward pressure on price is likely to be limited to the inflation rate as any additional price increase would need to be paid back to CMS in the form of inflation rebates.
Read More
Spending climbed by 2.7% in 2021. In 2020, it soared by 10.3%, fueled by federal government spending in response to the pandemic. The blizzard of calculations of 2021 healthcare spending by CMS’ actuaries also provides further evidence that utilization of healthcare services bounced back in 2021.
Read More